UNSPSC 51433402: Moexipril

This classification denotes an ace inhibitor with the molecular formula C27H34N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WT87C52TJZ, chemically known as (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester but generally known as moexipril, which bears US NIH Compound Identifier 91270. European Medicines Agency schedules Moexipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09030MIG.

UNSPSC 51433402 Moexipril (Commodity) represents pharmaceutical products for emergency medical use and state health programs, specifically ACE inhibitor medications and related cardiovascular agents procured by state agencies, municipalities, and cooperative purchasing alliances to supply emergency medical services, state health benefit programs, and institutional healthcare facilities. State and local governments buy this code primarily through emergency services departments (fire rescue, EMS), state health and human services commissions managing pharmacy benefit programs, and multi-state cooperative purchasing organizations aggregating pharmaceutical demand across member jurisdictions. Issuing bodies range from individual municipalities to statewide health agencies and regional purchasing alliances that bundle generic pharmaceuticals for distribution through authorized wholesalers to public facilities and employee health plans.

Recent activity spans Florida, Texas, and Minnesota through diverse procurement mechanisms. The City of Tampa's Purchasing Department issued an IFB (26P00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, soliciting four specific medication line items with an estimated contract value of $40,000 and a response deadline of April 8, 2026, with a one-year term and renewal options; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in early April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct state contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) with a contract effective July 1, 2026, and pricing evaluation weighted 75 percent on competitiveness.